| For: | Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74 [PMID: 36683719 DOI: 10.3748/wjg.v29.i1.61] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i1/61.htm |
| Number | Citing Articles |
| 1 |
Tien-Shin Chou, Daniel Hsiang-Te Tsai, Shieh-Chieh Shao, Edward Chia-Cheng Lai. SGLT-2 Inhibitor use and liver-related and mortality outcomes in patients with type 2 diabetes and compensated cirrhosis. BMC Medicine 2026; 24(1) doi: 10.1186/s12916-026-04629-x
|
| 2 |
Binqi Wang, Chan Gao, Juan Jin, Qiang He. Letter to the Editor: Interpreting the Clinical Applicability of SGLT‐2 Inhibitors in MASH‐Related Cirrhosis. Liver International 2026; 46(3) doi: 10.1111/liv.70564
|
| 3 |
Larisse Longo, Gabriel Guerreiro, Luiza Behrens, Matheus Pereira, Carlos Pinzon, Carlos Cerski, Carolina Uribe‑Cruz, Mário Álvares‑da‑Silva. Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal model. Biomedical Reports 2024; 22(1) doi: 10.3892/br.2024.1882
|
| 4 |
Aldo Torre, Jacqueline Córdova-Gallardo, Alberto C Frati Munari. Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier. Therapeutics and Clinical Risk Management 2023; doi: 10.2147/TCRM.S425292
|
| 5 |
J.A. Velarde-Ruiz Velasco, J. Crespo, A. Montaño-Loza, J.M. Aldana-Ledesma, A.D. Cano-Contreras, E. Cerda-Reyes, N.J. Fernández Pérez, G.E. Castro-Narro, E.S. García-Jiménez, J.E. Lira-Vera, Y.I. López-Méndez, J. Meza-Cardona, R. Moreno-Alcántar, J. Pérez-Escobar, J.L. Pérez-Hernández, D.K. Tapia-Calderón, F. Higuera-de-la-Tijera. Posicionamiento sobre manejo perioperatorio y riesgo quirúrgico en el paciente con cirrosis. Revista de Gastroenterología de México 2024; 89(3) doi: 10.1016/j.rgmx.2024.05.001
|
| 6 |
Yong He, Lu Chai, Han Chen, Xing-Shun Qi. Effect of different infusion approaches on safety and efficacy of terlipressin: Current controversies. World Chinese Journal of Digestology 2023; 31(17) doi: 10.11569/wcjd.v31.i17.705
Abstract(800) |
Core Tip(718) |
Full Article(HTML)(2547)
|
Times Cited (0)
|
Total Visits (3185)
|
Open
|
| 7 |
Christos Siafarikas, Chris J. Kapelios, Margarita Papatheodoridi, John Vlachogiannakos, Nikolaos Tentolouris, George Papatheodoridis. Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use. Liver International 2024; 44(4) doi: 10.1111/liv.15851
|
| 8 |
V. V. Tsukanov, A. V. Vasyutin, J. L. Tonkikh. Modern aspects of management of patients with metabolic dysfunction-associated steatotic liver disease. Meditsinskiy sovet = Medical Council 2025; (15) doi: 10.21518/ms2025-342
|
| 9 |
Kristina Baktikulova, Saulesh Kurmangaliyeva, Amin Tamadon, Kairat Kurmangaliyev, Nadiar M. Mussin, Ramazon Safarzoda Sharoffidin, Jurandir Fernando Comar. Prognostic Biomarkers for Predicting Decompensation in Alcoholic and Nonalcoholic Patients With Compensated Cirrhosis: An Umbrella Review. Biochemistry Research International 2026; 2026(1) doi: 10.1155/bri/9919068
|
| 10 |
J.A. Velarde-Ruiz Velasco, J. Crespo, A. Montaño-Loza, J.M. Aldana-Ledesma, A.D. Cano-Contreras, E. Cerda-Reyes, N.J. Fernández Pérez, G.E. Castro-Narro, E.S. García-Jiménez, J.E. Lira-Vera, Y.I. López-Méndez, J. Meza-Cardona, R. Moreno-Alcántar, J. Pérez-Escobar, J.L. Pérez-Hernández, D.K. Tapia-Calderón, F. Higuera-de-la-Tijera. Position paper on perioperative management and surgical risk in the patient with cirrhosis. Revista de Gastroenterología de México (English Edition) 2024; 89(3) doi: 10.1016/j.rgmxen.2024.05.001
|
| 11 |
Maxine W. Stachel, Eugene C. DePasquale. Optimizing cardiac status in the preliver transplant candidate. Current Opinion in Organ Transplantation 2024; 29(1) doi: 10.1097/MOT.0000000000001119
|
| 12 |
Wanting Yang, Gaoyue Guo, Chao Sun. Therapeutic potential of rifaximin in liver diseases. Biomedicine & Pharmacotherapy 2024; 178 doi: 10.1016/j.biopha.2024.117283
|
| 13 |
Càndid Villanueva, Dhiraj Tripathi, Jaume Bosch. Preventing the progression of cirrhosis to decompensation and death. Nature Reviews Gastroenterology & Hepatology 2025; doi: 10.1038/s41575-024-01031-x
|
| 14 |
Jonathan Soldera. Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease. Diagnostics 2026; 16(10) doi: 10.3390/diagnostics16101548
|
| 15 |
Xiangfeng Zeng, Sheiladevi Sukumaran. Research progress on the relationship between intestinal flora and liver cirrhosis. International Conference on Modern Medicine and Global Health (ICMMGH 2023) 2023; doi: 10.1117/12.2692644
|
| 16 |
Xue Li, Shi Liu, Jin Li, Ning Liu, Hui Li, An Ge, Liang Wang, Xie Dong, Hui Wang, Ju Liu, Lin Zhang, Hao Dong Zhang, Wei Gou. Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension. International Journal of General Medicine 2024; doi: 10.2147/IJGM.S453107
|
| 17 |
Camille A. Kezer, Annalisa Berzigotti, Brett E. Fortune, Douglas A. Simonetto. Drug treatments to prevent first decompensation in cirrhosis. Hepatology 2026; 83(6) doi: 10.1097/HEP.0000000000001117
|
| 18 |
Jun Zeng, Debesh Jha, Ertugrul Aktas, Elif Keles, Alpay Medetalibeyoglu, Matthew Antalek, Federica Proietto Salanitri, Amir A. Borhani, Daniela P. Ladner, Gorkem Durak, Ulas Bagci. Liver Cirrhosis Stage Estimation from MRI With Deep Learning. 2025 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2025; doi: 10.1109/EMBC58623.2025.11254659
|